Adaptive Biotechnologies Corporation

NasdaqGS:ADPT 株式レポート

時価総額：US$2.1b

Adaptive Biotechnologies 将来の成長

Future 基準チェック /16

Adaptive Biotechnologies利益と収益がそれぞれ年間50.7%と15.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に4.5% 50.5%なると予測されています。

主要情報

50.7%

収益成長率

50.52%

EPS成長率

Life Sciences 収益成長17.5%
収益成長率15.2%
将来の株主資本利益率4.53%
アナリストカバレッジ

Good

最終更新日18 May 2026

今後の成長に関する最新情報

Recent updates

ナラティブの更新 • May 17

ADPT: 2026 MRD Execution And Margin Discipline Will Support Future Upside Potential

Analysts now see Adaptive Biotechnologies' fair value edging from $20.57 to $20.14, reflecting mixed price target revisions. One firm cut its target by $3, while another raised its target by $2, as they update assumptions around growth, margins, the discount rate and future P/E expectations.
ナラティブの更新 • May 01

ADPT: 2026 MRD Outlook And Margin Discipline Will Drive Future Upside Potential

The updated analyst price target for Adaptive Biotechnologies moves slightly lower to about $20.57 from $20.86. Analysts attribute this change to modest adjustments to fair value estimates, discount rate assumptions, and longer term profit margin and P/E expectations.
ナラティブの更新 • Apr 16

ADPT: MRD Revenue Outlook And Refreshed Models Will Support Future Cash Flows

Narrative Update on Adaptive Biotechnologies The consensus analyst price target for Adaptive Biotechnologies has moved up by $1, reflecting updated analyst models that incorporate adjusted discount rates, refreshed revenue growth and profit margin assumptions, and a revised, still very large forward P/E framework. Analyst Commentary Recent Street research on Adaptive Biotechnologies centers on modestly higher price targets, with several bullish analysts revising their models at roughly the same time.
ナラティブの更新 • Apr 02

ADPT: MRD 2026 Outlook And Discount Assumptions Will Support Future Upside Potential

Analysts have raised their price targets on Adaptive Biotechnologies by about $1, reflecting updated views on discount rates, growth, margins, and future P/E assumptions. These changes keep the stock's fair value estimate effectively unchanged at around $21.
ナラティブの更新 • Mar 19

ADPT: MRD Outlook And Pfizer Agreements Will Support Future Cash Flows

Analysts have inched their average price targets on Adaptive Biotechnologies higher, often by about $1 increments. These changes reflect updated views that modestly adjust revenue growth, profit margin and future P/E assumptions while keeping the fair value estimate near $22.
ナラティブの更新 • Mar 04

ADPT: MRD And Pfizer Agreements Will Support Future Cash Flow Upside

The analyst price target for Adaptive Biotechnologies has shifted from $21.00 to $22.00. Analysts point to updated assumptions around growth, profitability, and long-term P/E expectations following a series of recent target increases across the Street.
ナラティブの更新 • Feb 18

ADPT: Pfizer Agreements And MRD Progress Will Support Future Upside Potential

Analysts have nudged their average price target for Adaptive Biotechnologies higher by about $1, reflecting updated fair value assumptions and slightly revised views on growth, margins and future P/E, in line with recent target increases from several research firms. Analyst Commentary Recent research updates cluster around modest target increases and a generally supportive view of Adaptive Biotechnologies, with most of the focus on refreshed fair value work rather than sweeping changes to the thesis.
ナラティブの更新 • Feb 03

ADPT: Sector Tailwinds And Pfizer Partnerships Will Support Measured Future Upside

Analysts have nudged their price targets on Adaptive Biotechnologies slightly higher, with Street research pointing to target increases such as TD Cowen moving to $20 from $19. This contributes to a modest lift in our fair value estimate from $20.00 to about $20.14 as they highlight solid expected sector results and fundamentals.
ナラティブの更新 • Jan 20

ADPT: Sector Tailwinds And Cancer Testing Leadership Will Support Future Upside

Narrative Update: Adaptive Biotechnologies The analyst price target for Adaptive Biotechnologies has moved from $19 to $20, reflecting updated views that incorporate recent Q4 preview work on diagnostics peers, expectations for solid sector results and 2026 outlooks, and the company’s latest Q3 report. Analyst Commentary Recent Street research around Adaptive Biotechnologies has focused on updated price targets that reflect fresh sector work and the company’s latest Q3 report.
ナラティブの更新 • Jan 05

ADPT: MRD Platform And Pfizer Agreements Will Support Long-Term Cash Flow Upside

Analysts have lifted their price target on Adaptive Biotechnologies to $16 from $11, citing the recent Q3 report as the key driver behind this updated view. Analyst Commentary Bullish Takeaways Bullish analysts point to the new US$16 price target, up from US$11, as a sign that expectations for execution and risk reward have shifted in a more constructive direction after the recent Q3 report.
Seeking Alpha • Dec 26

Adaptive Biotechnologies: 2026 Is The Durability Test, Not The Hype Cycle

Summary Adaptive Biotechnologies Corporation maintains a Hold rating as MRD segment momentum is offset by competitive and valuation concerns. ADPT's Q3 top-line strength was driven by a one-time Genentech payment; ex-Genentech, MRD revenue grew 52% Y/Y, showing underlying operational progress. MRD segment achieved standalone cash flow positivity, but consolidated profitability remains elusive without normalization; FY25 MRD guidance was raised. DLBCL market share defense and workflow integration are critical as competition intensifies, making 2026 a pivotal "prove it" year for ADPT. Read the full article on Seeking Alpha
ナラティブの更新 • Dec 15

ADPT: MRD Leadership Will Drive Long-Term Cash Flow Upside

Analysts have raised their fair value estimate for Adaptive Biotechnologies from approximately $15 to $21 per share. They cite higher long term profit margin expectations and confidence in the company’s leadership in minimal residual disease cancer testing, even with moderating revenue growth assumptions and a higher discount rate.
ナラティブの更新 • Nov 30

ADPT: Future Revenue Will Be Sustained By Leadership In Cancer Testing

Analysts have raised their fair value estimate for Adaptive Biotechnologies to $19.57 from $19.14. They cite increased confidence in the company's sustained revenue growth and leadership position in cancer testing.
ナラティブの更新 • Nov 16

ADPT: Future Revenue Will Be Driven By Market Expansion In Blood Cancer Testing

Analysts have raised their price target for Adaptive Biotechnologies by $2.00 to $19.14, citing the company's leadership in minimal residual disease testing, as well as expectations for sustained revenue growth and improved margins. Analyst Commentary Recent analyst discussions reveal diverse perspectives on Adaptive Biotechnologies' position in the market and future prospects.
ナラティブの更新 • Nov 01

ADPT: Leadership In Cancer Testing Will Drive Market Expansion And Execution Risks

Analysts have increased their price target for Adaptive Biotechnologies from $16.00 to $17.14 per share. They cite continuing leadership in cancer testing and expectations for robust revenue growth, driven by market expansion and operational improvements.
ナラティブの更新 • Oct 18

EMR Integration And Partnerships Will Reshape Clinical Diagnostics

Analysts have raised their price target for Adaptive Biotechnologies from $14.86 to $16.00. They cite the company’s strong positioning in cancer testing and sustained revenue growth potential.
分析記事 • Oct 16

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 31% Jump Shows Its Popularity With Investors

Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares have continued their recent momentum with a 31% gain in the...
ナラティブの更新 • Oct 04

EMR Integration And Partnerships Will Reshape Clinical Diagnostics

Analysts have increased their price target for Adaptive Biotechnologies from $14 to approximately $14.86 per share. They cite ongoing revenue growth momentum and strengthening leadership in the cancer diagnostics market as key drivers of the upward revision.
分析記事 • Sep 24

Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Aug 29

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 28% Share Price Bounce

Despite an already strong run, Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares have been powering on, with...
ナラティブの更新 • Aug 07

EMR Integration And Partnerships Will Reshape Clinical Diagnostics

Despite a modest decline in consensus revenue growth forecasts and a slight increase in the discount rate, the consensus analyst price target for Adaptive Biotechnologies has been raised from $11.86 to $13.29. What's in the News Raised full year 2025 MRD business revenue guidance to $190–200 million from the prior $180–190 million range; no revenue guidance for Immune Medicine.
分析記事 • May 31

Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 29% Higher

Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shareholders would be excited to see that the share price has had...
分析記事 • May 07

Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Debt In A Risky Way?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Apr 10

Why Investors Shouldn't Be Surprised By Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 26% Share Price Surge

The Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) share price has done very well over the last month, posting an...
User avatar
新しいナラティブ • Mar 25

ClonoSEQ And NovaSeq X Will Transform Clinical Testing Pipelines

Strategic partnerships and initiatives to raise test prices and efficiency are expected to drive substantial revenue and margin growth.
分析記事 • Feb 14

Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 40% Higher

Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares have continued their recent momentum with a 40% gain in the...
Seeking Alpha • Nov 26

Adaptive Biotechnologies: Making Some Progress

Summary Adaptive Biotechnologies posted strong Q3 results, beating expectations and reducing losses, while management has done a good job of reducing quarterly cash burn rates. The company's MRD segment, driven by clonoSEQ, continues to show significant growth, and the company's balance sheet remains strong. An updated analysis around Adaptive Biotechnologies follows in the paragraphs below. Read the full article on Seeking Alpha
分析記事 • Nov 26

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 25% Share Price Bounce

Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares have had a really impressive month, gaining 25% after a...
分析記事 • Nov 01

Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Oct 05

Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher

Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares have continued their recent momentum with a 27% gain in the...
分析記事 • Jul 12

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk

With a median price-to-sales (or "P/S") ratio of close to 3.3x in the Life Sciences industry in the United States, you...
分析記事 • May 08

Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Apr 03

It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks

To the annoyance of some shareholders, Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares are down a...

業績と収益の成長予測

NasdaqGS:ADPT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/2028428-1755N/A5
12/31/2027351-3919-48
12/31/2026287-72-17-438
3/31/2026295-50-30-27N/A
12/31/2025277-59-49-46N/A
9/30/2025253-80-63-61N/A
6/30/2025205-121-83-80N/A
3/31/2025190-142-89-85N/A
12/31/2024179-159-99-95N/A
9/30/2024177-195-115-110N/A
6/30/2024169-213-137-129N/A
3/31/2024175-215-145-136N/A
12/31/2023170-225-167-156N/A
9/30/2023180-196-171-159N/A
6/30/2023190-191-170-155N/A
3/31/2023184-195-195-179N/A
12/31/2022185-200-200-184N/A
9/30/2022168-221-231-208N/A
6/30/2022160-232-241-209N/A
3/31/2022155-229-248-199N/A
12/31/2021154-207-254-193N/A
9/30/2021147-190-241-179N/A
6/30/2021133-171-234-182N/A
3/31/2021116-155-208-176N/A
12/31/202098-146-168-150N/A
9/30/202092-122-148-137N/A
6/30/202092-99-131-120N/A
3/31/202093-82-115-105N/A
12/31/201985-70N/A205N/A
9/30/201978-62N/A227N/A
6/30/201969-56N/A245N/A
3/31/201959-53N/A252N/A
12/31/201856-46N/A-32N/A
12/31/201738-43N/A-35N/A

アナリストによる今後の成長予測

収入対貯蓄率: ADPT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ADPT今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ADPT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ADPTの収益 ( 15.2% ) US市場 ( 11.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: ADPTの収益 ( 15.2% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ADPTの 自己資本利益率 は、3年後には低くなると予測されています ( 4.5 %)。

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/20 11:27
終値2026/05/20 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Adaptive Biotechnologies Corporation 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13

アナリスト機関
Derik de BruinBofA Global Research
Mark MassaroBTIG
William BonelloCraig-Hallum Capital Group LLC